Alosaimi Fahad D, Abalhassan Mohammed, Alhaddad Bandar, Alzain Nasser, Fallata Ebtihaj, Alhabbad Abdulhadi, Alassiry Mohammed Z
Department of Psychiatry, King Saud University, Riyadh, Saudi Arabia.
Department of Medicine, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia.
Gen Hosp Psychiatry. 2017 Mar-Apr;45:62-69. doi: 10.1016/j.genhosppsych.2016.12.007. Epub 2016 Dec 19.
To evaluate the prevalence and clinical correlates of metabolic syndrome (MetS) and its components among patients with psychiatric disorders.
A cross-sectional study was conducted among adult patients with psychiatric disorders at major hospitals in Saudi Arabia. After measurements were recorded for all MetS components, demographic and clinical information was obtained mainly by reviewing the patients' medical charts.
The prevalence rate of MetS among the 992 study participants was 41.2%, high triglycerides was 32.8%, large waist circumference was 42.2%, high blood pressure was 42.5%, high fasting blood sugar was 47.8%, and low HDL cholesterol was 52.5%. Participants with MetS were more likely to be older, illiterate, divorced or widowed, have a higher number of children, older age of onset of psychiatric illness, longer duration of psychiatric disease, no previous psychiatric hospitalization, and have a history of diabetes and hypertension. After adjusting for significant demographic and clinical characteristics, none of the psychiatric diagnoses and treatments was independently associated with MetS, except the use of mirtazapine and venlafaxine.
The prevalence of MetS and its components among patients with psychiatric disorders is alarming irrespective of their diagnoses. Thus, metabolic screening especially among high risk groups is critical.
评估精神疾病患者中代谢综合征（MetS）及其各组分的患病率和临床相关性。
在沙特阿拉伯各大医院对成年精神疾病患者进行了一项横断面研究。记录所有MetS组分的测量值后，主要通过查阅患者病历获取人口统计学和临床信息。
992名研究参与者中MetS的患病率为41.2%，高甘油三酯为32.8%，大腰围为42.2%，高血压为42.5%，空腹血糖高为47.8%，高密度脂蛋白胆固醇低为52.5%。患有MetS的参与者更可能年龄较大、文盲、离婚或丧偶、子女数量较多、精神疾病发病年龄较大、精神疾病病程较长、既往无精神科住院史，并有糖尿病和高血压病史。在对显著的人口统计学和临床特征进行调整后，除使用米氮平和文拉法辛外，没有任何精神科诊断和治疗与MetS独立相关。
无论诊断如何，精神疾病患者中MetS及其组分的患病率都令人担忧。因此，尤其是在高危人群中进行代谢筛查至关重要。
